Details of the Drug
General Information of Drug (ID: DM0EKO5)
Drug Name |
Boldenone
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Boldenone; Dehydrotestosterone; 846-48-0; 1,2-Dehydrotestosterone; 1-Dehydrotestosterone; 1,2-Didehydrotestosterone; 17beta-Boldenone; delta1-Testosterone; Boldenonum; Boldenona; 17beta-Hydroxyandrosta-1,4-dien-3-one; 1,4-Androstadien-17beta-ol-3-one; Boldenonum [INN-Latin]; Boldenona [INN-Spanish]; Boldenone [INN:BAN]; UNII-5H7I2IP58X; 17beta-Hydroxyandrosta-1,4-diene-3-one; 17-beta-Hydroxyandrosta-1,4-dien-3-one; EINECS 212-686-0; NSC 79102; 17-beta-Hydroxy-17-alpha-1,4-androstadien-3-one; 5H7I2IP58X; CHEBI:34584
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 286.4 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 3.5 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 0 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
ADMET Property |
|
||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||